Browse WBSCR22

Summary
SymbolWBSCR22
NameWilliams Beuren syndrome chromosome region 22
Aliases MGC19709; MGC2022; MGC5140; PP3381; WBMT; MERM1; metastasis-related methyltransferase 1; HASJ4442; HUSSY-3; ......
Chromosomal Location7q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Nucleus, nucleoplasm Cytoplasm, perinuclear region Cytoplasm Note=Localized diffusely throughout the nucleus and the cytoplasm (PubMed:24488492). Localizes to a polarized perinuclear structure, overlapping partially with the Golgi and lysosomes (PubMed:25851604). Localization is not affected by glucocorticoid treatment (PubMed:24488492).
Domain PF08241 Methyltransferase domain
PF12589 Methyltransferase involved in Williams-Beuren syndrome
Function

S-adenosyl-L-methionine-dependent methyltransferase that specifically methylates the N(7) position of a guanine in 18S rRNA (PubMed:25851604). Requires the methyltransferase adapter protein TRM112 for full rRNA methyltransferase activity (PubMed:25851604). Involved in the pre-rRNA processing steps leading to small-subunit rRNA production independently of its RNA-modifying catalytic activity (PubMed:25851604). Important for biogenesis end export of the 40S ribosomal subunit independent on its methyltransferase activity (PubMed:24086612). Locus-specific steroid receptor coactivator. Potentiates transactivation by glucocorticoid (NR3C1), mineralocorticoid (NR3C2), androgen (AR) and progesterone (PGR) receptors (PubMed:24488492). Required for the maintenance of open chromatin at the TSC22D3/GILZ locus to facilitate NR3C1 loading on the response elements (PubMed:24488492). Required for maintenance of dimethylation on histone H3 'Lys-79' (H3K79me2), although direct histone methyltransferase activity is not observed in vitro (PubMed:24488492).

> Gene Ontology
 
Biological Process GO:0000154 rRNA modification
GO:0001510 RNA methylation
GO:0006364 rRNA processing
GO:0009451 RNA modification
GO:0016072 rRNA metabolic process
GO:0022613 ribonucleoprotein complex biogenesis
GO:0031167 rRNA methylation
GO:0032259 methylation
GO:0034470 ncRNA processing
GO:0042254 ribosome biogenesis
GO:0043414 macromolecule methylation
Molecular Function GO:0008168 methyltransferase activity
GO:0016741 transferase activity, transferring one-carbon groups
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-74160: Gene Expression
R-HSA-6790901: rRNA modification in the nucleus and cytosol
R-HSA-72312: rRNA processing
R-HSA-8868773: rRNA processing in the nucleus and cytosol
Summary
SymbolWBSCR22
NameWilliams Beuren syndrome chromosome region 22
Aliases MGC19709; MGC2022; MGC5140; PP3381; WBMT; MERM1; metastasis-related methyltransferase 1; HASJ4442; HUSSY-3; ......
Chromosomal Location7q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between WBSCR22 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolWBSCR22
NameWilliams Beuren syndrome chromosome region 22
Aliases MGC19709; MGC2022; MGC5140; PP3381; WBMT; MERM1; metastasis-related methyltransferase 1; HASJ4442; HUSSY-3; ......
Chromosomal Location7q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of WBSCR22 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.52 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolWBSCR22
NameWilliams Beuren syndrome chromosome region 22
Aliases MGC19709; MGC2022; MGC5140; PP3381; WBMT; MERM1; metastasis-related methyltransferase 1; HASJ4442; HUSSY-3; ......
Chromosomal Location7q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of WBSCR22 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0010.998
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2490.938
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1810.939
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3780.255
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2670.883
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5210.828
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0540.892
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2150.9
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1710.926
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2470.899
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0130.996
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1390.0438
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of WBSCR22 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolWBSCR22
NameWilliams Beuren syndrome chromosome region 22
Aliases MGC19709; MGC2022; MGC5140; PP3381; WBMT; MERM1; metastasis-related methyltransferase 1; HASJ4442; HUSSY-3; ......
Chromosomal Location7q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of WBSCR22. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolWBSCR22
NameWilliams Beuren syndrome chromosome region 22
Aliases MGC19709; MGC2022; MGC5140; PP3381; WBMT; MERM1; metastasis-related methyltransferase 1; HASJ4442; HUSSY-3; ......
Chromosomal Location7q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of WBSCR22. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by WBSCR22.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolWBSCR22
NameWilliams Beuren syndrome chromosome region 22
Aliases MGC19709; MGC2022; MGC5140; PP3381; WBMT; MERM1; metastasis-related methyltransferase 1; HASJ4442; HUSSY-3; ......
Chromosomal Location7q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of WBSCR22. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolWBSCR22
NameWilliams Beuren syndrome chromosome region 22
Aliases MGC19709; MGC2022; MGC5140; PP3381; WBMT; MERM1; metastasis-related methyltransferase 1; HASJ4442; HUSSY-3; ......
Chromosomal Location7q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of WBSCR22 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolWBSCR22
NameWilliams Beuren syndrome chromosome region 22
Aliases MGC19709; MGC2022; MGC5140; PP3381; WBMT; MERM1; metastasis-related methyltransferase 1; HASJ4442; HUSSY-3; ......
Chromosomal Location7q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between WBSCR22 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolWBSCR22
NameWilliams Beuren syndrome chromosome region 22
Aliases MGC19709; MGC2022; MGC5140; PP3381; WBMT; MERM1; metastasis-related methyltransferase 1; HASJ4442; HUSSY-3; ......
Chromosomal Location7q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting WBSCR22 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.